Qureight backed with 拢7m to tackle lung & heart disease
Qureight has raised almost 拢7 million in Series A funding to accelerate drug development in lung and heart disease. The Cambridge firm鈥檚 cloud platform leverages imaging data analytics and AI technology to help the best new drugs get approved. Its technology can be used by hospitals, clinical research organisations and multinational pharmaceutical companies to find … Continue reading Qureight backed with 拢7m to tackle lung & heart disease
